NasdaqGS:BIIBBiotechs
Biogen (BIIB) One Off US$1.1b Loss Tests Bullish Earnings Growth Narrative
Biogen (BIIB) has just opened its Q1 2026 season with recent quarterly figures that show Q4 2025 revenue of US$2.3 billion and a basic EPS loss of US$0.33, compared with Q4 2024 revenue of US$2.5 billion and EPS of US$1.83. The trailing net profit margin for the last twelve months sits at 13.1% versus 16.9% a year earlier, reflecting the impact of a US$1.1 billion one off loss on reported earnings. Over the last few quarters, revenue has moved from US$2.5 billion in Q4 2024 to US$2.4 billion...